MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24
March 24 2022 - 9:26AM
Business Wire
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the
Company”), a clinical-stage pharmaceutical company committed to
extending healthy lifespan, announced today that Dr. Adam Kaplin,
Chief Scientific Officer, will appear as a featured guest on the
Cheddar News Network show "Cheddar Innovates" on Thursday, March
24th, 2022 at 11:50am ET.
The appearance will be streamed online via Cheddar News.
Dr. Kaplin will discuss the business of aging and the Company's
Phase 2 clinical trial of lead candidate MYMD-1 as a therapy for
delaying aging and expanding health lifespan. He will address the
future of this projected $600 billion market and what the next
steps for MyMD will be towards bringing a drug to market.
"Cheddar Innovates," hosted by Alicia Nieves and Azia Celestino,
is a weekly show focused on the latest and greatest in history,
technology, science, and nature.
A replay of the appearance will be provided on the MyMD website
when available after its conclusion.
About MyMD Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical-stage
pharmaceutical company committed to extending healthy lifespan, is
focused on developing two novel therapeutic platforms that treat
the causes of disease rather than only addressing the symptoms.
MYMD-1 is a drug platform based on a clinical stage small molecule
that regulates the immune system to control TNF-α, which drives
chronic inflammation, and other pro-inflammatory cell signaling
cytokines. MYMD-1 is being developed to delay aging, increase
longevity, and treat autoimmune diseases and COVID-19- associated
depression. The Company’s second drug platform, Supera-CBD, is
being developed to treat chronic pain, addiction and epilepsy.
Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and
is being developed to address and improve upon the rapidly growing
CBD market, which includes both FDA approved drugs and CBD products
not currently regulated as drugs. For more information, visit
www.mymd.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release may contain forward-looking statements. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause actual results,
performance or achievements to be materially different from any
expected future results, performance, or achievements.
Forward-looking statements speak only as of the date they are made
and none of MyMD nor its affiliates assume any duty to update
forward-looking statements. Words such as "anticipate," "believe,"
"could," "estimate," "expect," "may," "plan," "will," "would'' and
other similar expressions are intended to identify these
forward-looking statements. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, without limitation: the timing
of, and MyMD’s ability to, obtain and maintain regulatory approvals
for clinical trials of MyMD’s pharmaceutical candidates; the timing
and results of MyMD’s planned clinical trials for its
pharmaceutical candidates; the amount of funds MyMD requires for
its pharmaceutical candidates; increased levels of competition;
changes in political, economic or regulatory conditions generally
and in the markets in which MyMD operates; MyMD’s ability to retain
and attract senior management and other key employees; MyMD’s
ability to quickly and effectively respond to new technological
developments; MyMD’s ability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary
rights of others and prevent others from infringing on MyMD’s
proprietary rights; and the impact of the ongoing COVID-19 pandemic
on MyMD’s results of operations, business plan and the global
economy. A discussion of these and other factors with respect to
MyMD is set forth in the Quarterly Report on Form 10-Q for the
quarterly period ended September 30, 2021, filed by MyMD on
November 12, 2021 (as amended on November 15, 2021).
Forward-looking statements speak only as of the date they are made
and MyMD disclaims any intention or obligation to revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220324005631/en/
Robert Schatz (646) 421-9523 rschatz@mymd.com www.mymd.com
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Apr 2023 to Apr 2024